XHKG
3737
Market cap81mUSD
Oct 09, Last price
0.74HKD
1D
-3.29%
1Q
6.52%
Jan 2017
-54.91%
IPO
-70.24%
Name
Zhongzhi Pharmaceutical Holdings Ltd
Chart & performance
P/E
30.55
P/S
0.30
EPS
0.02
Div yield, %
6.58%
Shrs. gr., 5y
-0.13%
Rev. gr., 5y
1.61%
Revenues
1.74b
-21.55%
Net income
17m
-81.84%
CFO
104m
-42.59%
Dividend
May 23, 20250.05 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
Key people
Tian Zhi Lai
Executive Chairman of the Board
Jiong Chen
General Manager - Honeson Pharmaceutica
Mei Fang Jiang
General Manager of Zhongzhi Chain Pharmacies
Wu Yi Li
General Manager of Zhongzhi Herb Pieces
Jun Xiao Cao
Executive Director
Jin Le Cheng
Executive Director · since 2016
Ying Feng Lai
Executive Director · since 2018
Li Mou
Chief Financial Officer, Executive Director
Lin Tang
Head of the technical department of Zhongzhi Pharmaceutical and chief engineer of Honeson Pharmaceutical
Wing Yan Ho
Company Secretary · since 2017
Jiang Li Xia Lai
Non-Executive Director · since 2016
Ai Xing Yang
Non-Executive Director · since 2018
Kwun Wan Ng
Non-Executive Independent Director
Kam Wah Wong
Non-Executive Independent Director
Dai Han Zhou
Non-Executive Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||